ALX Oncology says $147.2M should fund it past two data readouts into 2028
The US biotech's third-quarter loss was $21.8 million, and management says its balance sheet is sized to reach an EGFR-directed ADC update and a breast cancer Phase 2 result.
ALX Oncology ended the third quarter with $147.2 million in cash and investments. The company says that is enough to run the business into the first half of 2028. The figure was published on 16 November alongside a quarterly net loss of $21.8 million. The timeframe is management's own guidance, not an independent estimate.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Alx Oncology Holdings Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.